Copaxone Injection, Solution
Product Images NDC 68546-317

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Copaxone (NDC 68546-317). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Neuroscience, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image01 (Image 1)

A Kaplan-Meier curve graph comparing the percentage of second exacerbations over time between Copaxone and placebo groups. The x-axis shows days from 0 to 1080, and the y-axis represents the percent of second exacerbation up to 60%. The Copaxone group shows a lower cumulative incidence curve compared to placebo, indicating fewer second exacerbations over time.*

FDA Label Image

Figure G (Image 10)

An instructional illustration showing a hand administering a subcutaneous injection with a syringe into the thigh of a seated person. The image depicts the proper injection technique for a subcutaneous solution, consistent with the dosing route for Copaxone (Glatiramer Acetate).*

FDA Label Image

Figure H (Image 11)

An instructional illustration showing a person administering a subcutaneous injection in the abdominal area. The image focuses on the hands holding a syringe poised to inject, demonstrating proper injection technique for subcutaneous drug delivery.*

FDA Label Image

Figure I (Image 12)

An instructional illustration showing a hand holding a syringe with a needle poised above the skin of the opposite hand, demonstrating a subcutaneous injection technique.*

FDA Label Image

Figure J (Image 13)

Illustration showing a hand administering a subcutaneous injection with a syringe into the upper arm, indicating the correct injection technique related to Copaxone (Glatiramer Acetate) subcutaneous injection solution.*

FDA Label Image

Figure K (Image 14)

Illustration showing a person preparing for a subcutaneous injection by pinching the skin on their thigh. The image demonstrates proper technique for injecting Copaxone (Glatiramer Acetate) injection, solution.*

FDA Label Image

Figure L (Image 15)

An illustration of a biohazard sharps disposal container for medical waste. The container is rectangular with a lid on top and features a biohazard symbol on the front. It is commonly used to safely dispose of needles or injection equipment.*

FDA Label Image

Logo (Image 16)

FDA Label Image

20mg Carton (Image 17)

Copaxone 20 mg/mL injection solution carton label for subcutaneous use. Contains 30 single-dose pre-filled syringes of glatiramer acetate injection. The label indicates once daily use and includes manufacturer Teva Neuroscience, Inc. Storage instructions recommend refrigeration and protection from light.*

FDA Label Image

40mg Carton (Image 18)

Packaging label for Copaxone 40 mg/mL injection solution by Teva Neuroscience, Inc. The label states it is for subcutaneous injection only, supplied as 12 single-dose pre-filled syringes. The administration is indicated as three times a week. Storage instructions specify refrigeration between 36 to 48°F and protection from light.*

FDA Label Image

Image02 (Image 2)

Line graph comparing the cumulative number of enhancing lesions (median) over 9 months between Copaxone and placebo groups. The x-axis represents months, and the y-axis shows the cumulative number of enhancing lesions. The Copaxone group shows a lower cumulative lesion count than the placebo group over time.*

FDA Label Image

Logo (Image 3)

FDA Label Image

Figure A (Image 4)

An illustration showing components related to the injection process for Copaxone (Glatiramer Acetate) including a sharps disposal container, syringe in blister package, cotton balls, alcohol wipes, and an injection diary, arranged on a flat surface.*

FDA Label Image

Figure B (Image 5)

An instructional illustration showing hands preparing a Copaxone injection, solution for subcutaneous use. One hand holds an injection device while the other hand adjusts or inserts the needle or syringe, demonstrating proper handling technique for the medication.*

FDA Label Image

Figure C (Image 6)

Injection site illustration for Copaxone (Glatiramer Acetate) subcutaneous injection. Highlights recommended injection areas on the human body, including abdomen (avoiding around 2 inches from the belly button), back of hips and arms, fleshy areas of the upper back portion of the arms, and thighs (about 2 inches above the knee and 2 inches below the groin).*

FDA Label Image

Figure D (Image 7)

An illustration shows a person performing a subcutaneous injection by pinching the skin and inserting a small square adhesive patch or pad, likely demonstrating the injection site preparation or application technique for Copaxone injection solution.*

FDA Label Image

Figure E (Image 8)

A series of three black-and-white line drawings showing hands preparing a subcutaneous injection. The first image shows a hand holding a syringe ready to be capped or uncapped. The second image depicts one hand removing a protective cap from the needle of the syringe using the other hand. The third image shows one hand holding the syringe with the cap removed, with the cap lying on a flat surface nearby.*

FDA Label Image

Figure F (Image 9)

An instructional illustration showing a hand pinching the skin of a forearm, demonstrating a technique commonly used for subcutaneous injection administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.